van what have we had this for 6 months? $66 I believe - finally it starts to move - Copper at a high<----- SCCO Southern Copper Corporation 68.942.93(+4.44%)<--------------
Kicking myself $42 a nice entry price. What I'm realizing is if you buy well you can hold the damn stock. These sharp corrections are shaking me out because my buy points are too high.
AbbVie’s guidance for Skyrizi and Rinvoq lifts remaining overhang - Morgan Stanley ABBV Morgan Stanley has welcomed the recent sales guidance issued by AbbVie (ABBV-0.4%) for Rinvoq (upadacitinib) and Skyrizi (risankizumab). Ina press release on Tuesday ahead of its presentation at the ongoing J.P. Morgan Healthcare Conference, the North Chicago, Illinois-based biotech reaffirmed its previous revenue guidance of more than $15B risk-adjusted sales for the treatments in 2025. While lowering the Rinvoq sales guidance to over $7.5B from more than $8.5B previously, the company has raised the Skyrizi sales guidance to more than $7.5B from over $7.0B, the analysts led by Matthew Harrison point out. “The announcement is a positive for ABBV because it removes the last overhang where investors previously believed that mgt. would need to lower its earlier guidance given JAK label safety concern,” they wrote. The update suggests management's expectations over a potential FDA approval for Rinvoq in atopic dermatitis (AD), the team added. Morgan Stanley has an Overweight rating on AbbVie(NYSE:ABBV)with a price target of $124 per share. Meanwhile, commenting on AbbVie’s sales update, BMO analyst Gary Nachman argues that the “bullish update at JPM reaffirmed confidence in the long-term growth prospects for the company post the Humira LOE next year.” Nachman also notes AbbVie management “stressed that solid growth is expected with Immunology franchise well beyond 2025 (should ultimately exceed Humira’s peak).” BMO, with an Outperform rating on the stock, has raised the price target to $153 from $134 per share in reaction. Skyrizi is an IL-23 inhibitor currently approved for plaque psoriasis. Rheumatoid arthritis therapy, Rinvoq belongs to JAK inhibitors, a drug category that has recently come under FDA scrutiny over safety concerns.
I have one account that is filled with such speculative stuff i am afraid to look at it. That's not good. It did have ECOR in there and I'm pretty sure I sold it when it slipped from $1. 99% sure. I kind of let you al down today because I saw this news but my nasty attitude towards the name prevented me from recommending it as a gummy less it flop.. But it was up 8% and then went + 20%. ElectroCore wins FDA’s Breakthrough Designation for gammaCore nVNS device in PTSD Jan. 12, 2022 8:40 AM ETelectroCore, Inc. (ECOR) Grandbrothers/iStock Editorial via Getty Images electroCore(NASDAQ:ECOR)hasadded ~8.1% in the pre-market after announcing that the FDA granted the Breakthrough Designation forits gammaCore nVNS device as a treatment for posttraumatic stress disorder (PTSD). The decision follows evidence indicating that nVNS cut the PTSD symptoms by 31% compared to a sham stimulation. The research was conducted by a team of scientists led by J. Douglas Bremner in the Departments of Psychiatry and Radiology at the Emory University School of Medicine and Omer T. Inan at the Georgia Institute of Technology in Atlanta, Georgia. “gammaCore represents a new class of treatment separate from medication or psychotherapy,” Dr. Bremner remarked. It “does not involve costly and invasive procedures for implantation, like previous VNS devices approved by the FDA for treatment of refractory depression,” he added.
4/11/2016 I bought MELI 250 shares @ $127 Forget when I sold I think $300.... MELI NOW COSTS MELI MercadoLibre, Inc. 1,197.0130.94(+2.65) WTF! > Is this the greatest stock of all time?
Natural gas is on thew rise. This LP yields 7.75% and never misses a payment they just made a questionable purchase of Natural gas fields but the timing is probably right. "As an investment, EPD has been a reliable dividend company with 23 years of annual dividend growth under its belt. EPD has been able to manage the swings of the volatile energy industry through prudent balance sheet management. With a BBB+ credit rating, EPD has the highest credit rating in its sector. EPD has generously rewarded investors while also becoming fully self-funding." Market Cap $51.41B PE (FWD) 11.06 Yield (FWD) 7.78% Rev Growth (YoY) 29.54% Short Interest 2.07% TOTAL RETURN POTENTIAL HERE IS QUITE LARGE-
Yesterday Enterprise Products Partners (EPD)announcedit agreed to acquire Navitas Midstream, a private Midland Basin natural gas gathering and processing (G&P) operator, for $3.25 billion in cash. EPD is acquiring Navitas with no debt and is funding the acquisition with cash on hand and short-term borrowings. EPD expects the deal to close in the first quarter. Navitas is backed by Warburg Pincus, which pursued a typical oil & gas private equity investment strategy of growing both organically and by acquiring smaller operators before selling out to a larger public entity. East Daley estimates that Navitas’ throughput grew by approximately 46% in 2020 and 35% in 2021. EPD pointed to 30% growth in 2022, bringing Navitas’ throughput to 1.3 Bcf/d. At the moment, EPD lacks a meaningful natural gas and natural gas liquids (NGL) presence in the Midland Basin, one of the fastest-growing and most economic shale basins in the U.S. The Navitas acquisition provides EPD with an attractive position in the basin’s core, with acreage dedicated to it by a diverse roster of more than 40 E&P customers. EPD website